Study Of Cabaser and Sinemet CR For The Treatment Of Nighttime Symptoms Associated With Parkinson's Disease.
A Double-Blind, Randomized, Comparative Study of Cabaser and Sinemet CR For The Treatment Of Nocturnal Disability In Levodopa -Treated Parkinson's Disease Patients.
Sponsor: Pfizer
Terminated
See Detailed Description for termination reason.
Other terminated trials from Pfizer
Other Parkinson Disease trials with similar outcome
Listed as NCT00174239, this PHASE4 trial focuses on Parkinson Disease and remains terminated or withdrawn. Sponsored by Pfizer, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE4
First recorded
Jul 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Bologna, Italy , Bolzano, Italy , Brisbane, Australia , Loc. Camerelle - Pozzilli, Italy , Madrid, Spain , Napoli, Italy , Oviedo, Spain , Padua, Italy , Palermo, Italy and 4 more locations